Oncology
[Oncology archives]

1. Bechan GI, Lee DW, Zajonc DM, Heckel D, Xian R, Throsby M, van Meijer M, Germeraad WT, Kruisbeek AM, Egeler RM, Arceci RJ. Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity. Br J Haematol. 2012 Nov;159(3):299-310.
Key words: phage, monoclonal, cytolytic
http://www.ncbi.nlm.nih.gov/pubmed/22934889

2. Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22;120(22):4285-91.
Key words: sickle cell, cyclophosphamide, donor
http://www.ncbi.nlm.nih.gov/pubmed/22955919

3. Isaacs JT, Antony L, Dalrymple S, Brennen WN, Gerber S, Hammers H, Wissing MD, Kachhap SK, Luo J, Xing L, Bjork P, Olsson A, Björk A, Leanderson T. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2012 Nov 13. [Epub ahead of print]
Key words: HDAC4, allosteric, signaling
http://www.ncbi.nlm.nih.gov/pubmed/23149916

4. Jackson CM, Flies DB, Mosse CA, Parwani A, Hipkiss EL, Drake CG. Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. Prostate. 2012 Nov 5. doi: 10.1002/pros.22606. [Epub ahead of print]
Key words: prostatisis, aotoimmune
http://www.ncbi.nlm.nih.gov/pubmed/23129407

5. Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012 Nov;97(11):1736-42.
Key words: leukemia, mitoxantrone, flavopiridol
http://www.ncbi.nlm.nih.gov/pubmed/22733022

6. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Nov 19. [Epub ahead of print]
Key words: arabinoside, leukemia, selective checkpoint
http://www.ncbi.nlm.nih.gov/pubmed/23092873

7. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA Jr, Velculescu VE. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012 Nov 28;4(162):162ra154.
Key words: circulation, chromosomal, sequencing
http://www.ncbi.nlm.nih.gov/pubmed/23197571

8. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable Cancer Regression Off-treatment and Effective Re-induction Therapy with an Anti-PD-1 Antibody. Clin Cancer Res. 2012 Nov 20. [Epub ahead of print]
Key words: cancer regression, anti-PD, Re-induction
http://www.ncbi.nlm.nih.gov/pubmed/23169436

9. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):E3367-76.
Key words: breast cancer, hypoxia, coactivator
http://www.ncbi.nlm.nih.gov/pubmed/23129632

10. Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012 Dec;17(4):469-92.
Key words: papillomavirus, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/23163511

11. Rais R, Zhao M, He P, Xu L, Deeken JF, Rudek MA. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomed Chromatogr. 2012 Nov;26(11):1315-24.
Key words: sunitinib, human plasma, pharmacokinetic
http://www.ncbi.nlm.nih.gov/pubmed/22259028

12. Ren YR, Chaerkady R, Hu S, Wan J, Qian J, Zhu H, Pandey A, Kern SE. Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin. J Proteome Res. 2012 Nov 2;11(11):5301-10.
Key words: mesothelin, therapeutic, control locus
http://www.ncbi.nlm.nih.gov/pubmed/23025254

13. Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012 Nov 15;120(20):4205-14.
Key words: Myeloid, terminal, FLT3
http://www.ncbi.nlm.nih.gov/pubmed/23012328

14. Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J. 2012 Nov;18(6):642-52.
Key words: vaccines, pancreatic cancer
http://www.ncbi.nlm.nih.gov/pubmed/23187853

Return to top of Publications - Oncology